A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens.
Biovectors (BV) are a new family of protein carriers. They are nanoparticles of polymerized polysaccharides substituted with phosphate residues and surrounded by covalently bound lipid molecules (palmitic acid). The effect of BV was tested on the immunogenicity of rabies antigens. Biovectors enhanced the production of antibody induced by both rabies glycoprotein and ribonucleoprotein. Moreover, they enhanced the protective activity of an experimental rabies vaccine composed of inactivated and purified virus. The isotype profile of antibody produced in vivo was not modified when BV were mixed with rabies antigens. To clarify the mechanism of the adjuvant/ immunostimulation effect of BV, two types of approach were used: (1) analysis of the antibody response when antigen and BV were injected separately; (2) determination of the nature of cells involved in the proliferation in vitro of murine splenocytes in the presence of BV. The enhancing effect of BV on antibody production was highest when mixed with antigens. In vitro BV induced the proliferation of B cells. These findings suggest that BV have immunostimulating properties in addition to their probable depot and/or antigen-presentation effect which explain in part their adjuvant activity.
Castignolles
N
N
Laboratoire des Lyssavirus, Institut Pasteur, Paris, France.
Morgeaux
S
S
Gontier-Jallet
C
C
Samain
D
D
Betbeder
D
D
Perrin
P
P
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000956:Antigens, Viral / Q000276:immunology*; D004337:Drug Carriers; D005260:Female; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D011134:Polysaccharides / Q000008:administration & dosage; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D004337:Drug Carriers; D011134:Polysaccharides; D011819:Rabies Vaccines